The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Fixed-duration teclistamab and talquetamab for frail patients with NDMM in FITFIX: trial-in-progress
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the upcoming FITFIX study (NCT07107529), which will investigate fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma (NDMM). Dr Schjesvold highlights the potential benefits of this approach, including avoiding toxic treatments and the fixed duration of treatment with the option to restart upon progression. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
